Issue |
Med Sci (Paris)
Volume 38, Number 11, Novembre 2022
Genre
|
|
---|---|---|
Page(s) | 905 - 912 | |
Section | M/S Revues | |
DOI | https://doi.org/10.1051/medsci/2022151 | |
Published online | 30 November 2022 |
Hormonothérapies de transition chez les personnes transgenres
Gender-affirming hormone therapy in transgender persons
Service de gynécologie obstétrique, médecine de la reproduction, hôpital Tenon, AP-HP, Sorbonne université, Paris, France
*
nicolai.johnson@aphp.fr
**
nathalie.chabbert-buffet@aphp.fr
Aujourd’hui encore, la prise en charge médicale des personnes transgenres pâtit d’une insuffisance d’offre de soins et de formation des soignants. La mise en œuvre d’une hormonothérapie est souvent souhaitée par les personnes transgenres et il est nécessaire qu’un médecin sache l’instaurer et la suivre tout au long de la transition. Nous abordons dans cette revue le traitement hormonal féminisant (THF) chez les femmes transgenres adultes, et le traitement hormonal masculinisant (THM) chez les hommes transgenres adultes.
Abstract
Medical care for transgender patients is still characterized by an insufficient availability of healthcare services, as well as by poor provider education and training. Transgender patients often require gender-affirming hormone therapy (GAHT), and physicians, including endocrinologists, general practitioners, and others, should be trained to initiate and monitor these treatments throughout the transition process, and beyond. This article will address the specific issues surrounding GAHT in adult transgender women and men.
© 2022 médecine/sciences – Inserm
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.